title: [Clinical evaluation of laser in situ keratomileusis operation with three different ablative patterns].
abstract: To evaluate the clinical outcome among three different laser in situ keratomileusis (LASIK) ablations: Q-factor customized ablation (aberration smart ablation, ASA), wave-front guided ablation (WASCA) and ablation under wave-front guiding plus iris recognition system (IR+WASCA).
  
  
  
  This prospective study comprised 96 eyes of 96 patients, and they were randomly divided into three groups: 30 patients in ASA group, 32 in WASCA group, and 34 in IR+WASCA group. There were no any statistical differences in spherical equivalent (SE), age, sex, pupil diameter, higher-order aberrations (HOA) among three groups preoperatively. Wave-front analysis was performed before and 1, 3 months after operation.
  
  
  
  All patients got an uncorrected visual acuity (UCVA) ≥ 0.8 1 and 3 months after operation. The residual SE was in ± 0.50D both at 1 and 3 months after surgery. There was no statistical difference in SE value, HOA, change of HOA, and coma aberration postoperatively among three groups. Horizontal coma (Z3¹) aberration took the majority of coma. HOA, total coma aberrations and spherical aberration increased postoperatively (P = 0.000), but without significant difference between 1 month and 3 months after surgery.
  
  
  
  That three customized LASIK are all effective, safe, accurate and stable; meanwhile WASCA may have better UCVA than the other two groups postoperatively.
authors.affiliation: The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China. borneymao@gmail.com
authors.forename: Ling-na
authors.initials: LN
authors.lastname: Mao
authors.forename: Wen-jun
authors.initials: WJ
authors.lastname: Jiang
authors.forename: Ya-bo
authors.initials: YB
authors.lastname: Yang
mesh_terms: D005500:Follow-Up Studies; D006801:Humans; D020731:Keratomileusis, Laser In Situ / Q000379:methods*; D009216:Myopia / Q000601:surgery*; D011446:Prospective Studies; D016896:Treatment Outcome